CXCL10 and cancer: In addition to anti-PD-L1-IFN-α, we also generated an anti-EGFR-hIFN-α fusion protein and likewise, targeting human IFN-α to EGFR positive human cancer cells (Geo and H747) demonstrated superior IP-10 induction compared with controls (Fig 2D).